Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06421636 · ClinicalTrials.gov registry record · Phase 2
A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body
A Phase 2 study of Non-Transfusion Dependent Beta-Thalassemia (NTDT), sponsored by Regeneron Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 95
- Enrollment target
- 20
- Study locations
NCT06421636 is a Phase 2 study of Non-Transfusion Dependent Beta-Thalassemia (NTDT) that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 95 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT06421636, a Phase 2 study of Non-Transfusion Dependent Beta-Thalassemia (NTDT), is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 95 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is researching an experimental drug called REGN7999 (called "study drug"). The study is focused on patients with non-transfusion dependent beta-thalassemia. The aim of the study is to see how safe and effective the study drug is. The study is looking at several other research questions, including: * Whether the study drug lowers extra iron levels in the body * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG REGN7999
Study Locations (20)
Other
- K Eristavi National Center of Experimental and Clinical Surgery - Tbilisi
- Medinvest Institute of Hematology and Transfusiology Limited - Tbilisi
- University Hospital of Ioannina - Ioannina
- Day Hospital Thalassemia and Haemoglobinopathies (DHTE); A.O.U S.Anna - Ferrara
- Hospital Tunku Ampuan Besar Tuanku Aishah Rohani (HPKK UKM) - Kuala Lumpur
- Chulalongkorn University - Bangkok
Attica
- Children's Hospital Agia Sophia - Athens
- Laiko General Hospital of Athens - Athens
Gujarat
- Hemato-Oncology Clinic Ahmedabad PVT. LTD. - Ahmedabad
- Nirmal Hospital Pvt. Ltd - Surat - Surat
National Capital Territory of Delhi
- All India Institute of Medical Sciences, New Delhi - New Delhi
- Indraprastha Apollo Hospitals - New Delhi
New York
- Weill Cornell Medicine - New York
Kerala
- Amrita Institute of Medical Sciences and Research Centre (AIMS) - Kochi
Maharashtra
- K J Somaiya Super Specialty Hospital & Research Centre - Mumbai
Rajasthan
- JK Lon Hospital - Jaipur
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2024-09-30 |
| Est. Completion | 2028-01-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06421636
The ClinicalTrials.gov registry entry for NCT06421636 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Transfusion Dependent Beta-Thalassemia (NTDT) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06421636 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, Attica, Gujarat.
Frequently Asked Questions
What is clinical trial NCT06421636 about?
NCT06421636 is a clinical study titled "A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body". This study is researching an experimental drug called REGN7999 (called "study drug"). The study is focused on patients with non-transfusion dependent beta-thalassemia. The aim of the study is to see how safe and effective the study drug is. The study is looking at several other research questions, ...
What is the current status of trial NCT06421636?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 95 participants. The study started on 2024-09-30. Estimated completion is 2028-01-24.
What conditions does trial NCT06421636 study?
This clinical trial studies the following conditions: Non-Transfusion Dependent Beta-Thalassemia (NTDT).
What interventions are being tested in trial NCT06421636?
The interventions under investigation include: Placebo (DRUG), REGN7999 (DRUG).
Who is sponsoring clinical trial NCT06421636?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06421636 being conducted?
This trial has 20 study locations across New York, Attica, Gujarat, Kerala, Maharashtra. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.